#United States #Minneapolis #UroMems #medical technology #Dan Rose

UroMems Welcomes Dan Rose as New Chairman

UroMems, a trailblazer in the medical technology sector, has made a significant announcement with the appointment of Dan Rose as its new chairman. This strategic move marks a pivotal moment for the company, especially as it gears up for critical clinical trials for its groundbreaking product, UroActive, in the United States and Europe.

A Visionary in Medical Devices

Dan Rose is a respected figure in the medical devices industry, bringing over 25 years of experience to UroMems. His impressive career trajectory includes roles as the CEO of notable companies such as Endovascular Engineering and LimFlow S.A., where he showcased his leadership abilities. At LimFlow, he played a crucial role in the company's successful acquisition by Inari Medical, valued at up to 415 million dollars. Rose's extensive background in product marketing and development positions him well to help UroMems thrive, particularly as it aims for large-scale clinical approval studies for UroActive.

Exciting Times for UroMems

Hamid Lamraoui, UroMems' co-founder and CEO, expressed enthusiasm over Rose's appointment during a challenging but promising time for the company. "Dan's proven track record and dynamic leadership will guide UroMems as we embark on the next phase of our clinical trials and prepare for the market launch of the first smart automated artificial urinary sphincter to treat stress urinary incontinence (SUI)," he stated.

The product in focus, UroActive, represents a revolutionary approach to managing SUI, a condition affecting an estimated 40 million Americans and 90 million Europeans. This innovative device is designed to significantly enhance patients' quality of life, addressing an often taboo but pervasive health issue.

Research and Development Milestones

Under Rose's leadership, UroMems is positioned to build on prior successes and crucial milestones in research and development. The company recently secured 47 million dollars in funding, a feat achieved following outstanding results from its initial multicenter clinical studies. This financial backing offers a solid groundwork for the company as it continues to innovate in a rapidly evolving medical landscape.

Understanding Stress Urinary Incontinence (SUI)

SUI is characterized by involuntary urinary leakage, a condition that can lead to significant psychological impacts such as depression, low self-esteem, and social stigma. UroMems aims to tackle these challenges through its patented technology. The platform behind UroActive is protected by over 150 patents and utilizes state-of-the-art engineering to optimize safety, patient experience, and surgical convenience.

UroActive stands out as the first active implantable electronic artificial urinary sphincter designed to compensate for urinary sphincter deficiency in both men and women with SUI. Its sophisticated mechatronic platform integrates intelligent, digital, and robotic systems to ensure functionality and comfort.

Despite its groundbreaking technology, UroActive has not yet received approval from the FDA and is not currently available for sale in the United States or Europe. However, the ongoing research and trials are expected to pave the way for its availability in the near future.

Looking Ahead

Dan Rose's leadership at UroMems comes at a time ripe with opportunity. His commitment to enhancing the lives of SUI patients resonates with the company's mission to innovate and provide effective solutions. As the company prepares to navigate the complex landscape of clinical approvals and market introduction, the medical community watches closely.

For more details about UroMems' mission or to stay updated on their progress, please visit www.uromems.com.

Media contact:
Shelli Lissick
Email: shelli.lissick@example.com
Phone: 651-276-6922